Showing 371-380 of 5059 results for "".
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class.
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Phase 3 Data: Sun Pharma’s Winlevi Is Safe and Effective Acne Txhttps://practicaldermatology.com/news/phase-3-data-sun-pharmas-winlevi-is-safe-and-effective-acne-tx/2461134/Results from two Phase 3 pivotal clinical trials showed favorable safety and efficacy data for Winlevi (clascoterone) cream 1% in patients with acne aged 12 years and older. The findings were presented at the American Academy of Dermatol
- Solta Medical Files for IPOhttps://practicaldermatology.com/news/solta-medical-files-for-ipo/2461072/Bausch Subsidiary Solta Medical Corporation is getting ready to go public. The Company publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of Solta's common shares.
- New Patient Satisfaction Data from Dermavant's PSOARING 3 Trial of Tapinarof in Adults with Plaque Psoriasishttps://practicaldermatology.com/news/new-patient-satisfaction-data-from-dermavants-psoaring-3-trial-of-tapinarof-in-adults-with-plaque-psoriasis/2461043/Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof
- New Data Show Itch Reduction with Topical Roflumilast in Psoriasis and Seborrheic Dermatitishttps://practicaldermatology.com/news/new-data-show-itch-reduction-with-topical-roflumilast-in-psoriasis-and-seborrheic-dermatitis/2460937/New patient-reported outcomes data show once-daily, topical roflumilast provides significant reductions in itch. Once-daily roflumilast cream reduced both the severity and burden of itch, and improved quality of life in the DERMIS-1 and DERMIS-2 Phase 3 pivotal studies in chronic plaque psoriasis
- Sun Pharma, Cassiopea Move Ahead with Winlevi Agreementhttps://practicaldermatology.com/news/sun-pharma-cassiopea-move-ahead-with-winlevi-agreement/2460899/Sun Pharma and Cassiopea SpA announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%).
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary en
- Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safehttps://practicaldermatology.com/news/hoth-therapeutics-incs-biolexa-in-ad-so-far-so-safe/2460853/Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis.